share_log

Morgan Stanley Maintains Equal-Weight on Cytek Biosciences, Lowers Price Target to $8

Morgan Stanley Maintains Equal-Weight on Cytek Biosciences, Lowers Price Target to $8

摩根士丹利維持對Cytek Biosciences的同等權重,將目標股價下調至8美元
Benzinga ·  2023/10/24 08:27

Morgan Stanley analyst Tejas Savant maintains Cytek Biosciences (NASDAQ:CTKB) with a Equal-Weight and lowers the price target from $13 to $8.

摩根士丹利分析師Tejas Savant維持賽特克生物科學公司(納斯達克:CTKB)的同等權重,並將目標價從13美元下調至8美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論